Thomas Yeung

Thomas Yeung

Expertise: Fundamental Analysis, Quant-Based Investing, Tax Analysis

Education: BA, Economics, Princeton University

Awards & Accomplishments: CFA Charterholder, IRS Enrolled Agent

Thomas Yeung, CFA, is a Market Analyst at InvestorPlace.com, where he helps investors navigate the world of finance with one of the most powerful tools available: knowledge. Tom brings over a decade of experience in company, commodity and industry analysis.

He is the current editor of the Omnia Portfolios, the highest-tier subscription at InvestorPlace and the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.

Tom started his investment career at Harding Loevner, a $40 billion asset management firm. Today, he works with InvestorPlace.com to help individuals and families identify great investments.

Tom holds a BA in Economics from Princeton University, where he graduated with high honors. He is a CFA® Charterholder and also a FINRA Registered Investment Adviser.

Recent Articles

2 Companies Tackling the AI Bottlenecks 

To give you a sense of these “Golden Rivet” makers Eric discusses in his latest presentation, I’d like to highlight two companies at the forefront of the AI bottlenecks… and that have been overlooked by Wall Street almost entirely so far.

2 Stocks to Buy to “Future-Proof” Your Portfolio

At its core, the former gatekeepers of AI technologies are quickly seeing their dominance vanish... some from supply chains catching up, and others due to AI itself.

3 Stocks to Buy During the Hormuz Crisis — and Why

War in Iran has turned the Strait of Hormuz into a global flashpoint — and with it, roughly 20% of the world's oil supply is…

2 Breakout Stocks to Buy Immediately  

Today, I’d like to share two stocks that demonstrate the power of Luke’s Breakout System – companies with hidden catalysts that could be entering the early stages of a major move. 

Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash

Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares…